Infectious Diseases

Back to articles

Extended-pulsed fidaxomicin a good option for C. difficile infections

KEY POINT

Use of extended-pulsed fidaxomicin (Dificid–Merck) was superior to standard-dose vancomycin when given to older patients with Clostridium difficile infections with respect to sustained clinical cure rates 30 days after the end of treatment, according to results of a trial published in Lancet Infectious Diseases.